✦ LIBER ✦

Treatment of paget's disease of bone with the new bisphosphonate ibandronate (BM 21.0955) by intravenous injection and continuous infusion

✍ Scribed by Knaus, J.; Grauer, A.; Seibel, M.J.; Ziegler, R.

Book ID: 123126534
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 160 KB
Volume: 17
Category: Article
ISSN: 8756-3282
DOI: 10.1016/8756-3282(96)88009-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Administration of the bisphosphonate iba

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

✍ Martin Pecherstorfer; Heinz Ludwig; Karl Schlosser; Signe Buck; Hermann-Josef Hu 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 615 KB

## Abstract Bisphosphonates (BPs) are used for the treatment of both benign and malignant diseases characterized by increased bone resorption. Because of their potential nephrotoxicity, currently available BPs have to be administered by slow intravenous infusion, with conventional doses requiring a

Alemtuzumab by continuous intravenous in

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Erratum: Alemtuzumab by continuous intra

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views